This report studies the CRISPR And CRISPR-Associated (Cas) Genes market. Clustered regularly interspaced short palindromic repeats (CRISPR) are segments of prokaryotic DNA containing short repetitions of base sequences. Each repetition is followed by short segments of "spacer DNA" from previous exposures to a bacteriophage virus or plasmid. The CRISPR/Cas system is a prokaryotic immune system that confers resistance to foreign genetic elements such as those present within plasmids and phages, and provides a form of acquired immunity. CRISPR associated proteins (Cas) use the CRISPR spacers to recognize and cut these exogenous genetic elements in a manner analogous to RNA interference in eukaryotic organisms. CRISPRs are found in approximately 40% of sequenced bacterial genomes and 90% of sequenced archaea. Cas9 was the first nuclease discovered, followed by Cpf1, which was discovered in the CRISPR/Cpf1 system of Francisella novicida. Other such systems are thought to exist. CRISPR/Editas Medicinec2 from the bacterium Leptotrichia shahii is RNA-guided CRISPR system that targets RNA rather than DNA, and can either cleave single-stranded RNA targets or knock them down. By delivering the Cas9 nuclease complexed with a synthetic guide RNA (gRNA) into a cell, the cell's genome can be cut at a desired location, allowing existing genes to be removed and/or new ones added. The Cas9-gRNA complex corresponds with the CAS III crRNA complex in the above diagram. CRISPR/Cas genome editing techniques have many potential applications, including altering the germline of humans, animals, and food crops. The use of CRISPR Cas9-gRNA complex for genome editing was the AAAS's choice for breakthrough of the year in 2015. Bioethical concerns have been expressed about the prospect of using this nascent biotechnology for editing the human germline. LPI (LP Information)' newest research report, the “CRISPR and CRISPR-Associated (Cas) Genes Industry Forecast” looks at past sales and reviews total world CRISPR and CRISPR-Associated (Cas) Genes sales in 2022, providing a comprehensive analysis by region and market sector of projected CRISPR and CRISPR-Associated (Cas) Genes sales for 2023 through 2029. With CRISPR and CRISPR-Associated (Cas) Genes sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CRISPR and CRISPR-Associated (Cas) Genes industry. This Insight Report provides a comprehensive analysis of the global CRISPR and CRISPR-Associated (Cas) Genes landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on CRISPR and CRISPR-Associated (Cas) Genes portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global CRISPR and CRISPR-Associated (Cas) Genes market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CRISPR and CRISPR-Associated (Cas) Genes and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CRISPR and CRISPR-Associated (Cas) Genes. The global CRISPR and CRISPR-Associated (Cas) Genes market size is projected to grow from US$ 1354.3 million in 2022 to US$ 10020 million in 2029; it is expected to grow at a CAGR of 33.1% from 2023 to 2029. Thermo Fisher Scientific, Editas Medicine, Caribou Biosciences, CRISPR therapeutics and Intellia therapeutics, Inc. are the top 5 players of CRISPR and CRISPR-Associated (Cas) Genes, with about 63% market shares. CRISPR And CRISPR-Associated (Cas) Genes industry is relatively concentrated, manufacturers are mostly in the Europe and North America. Among them, North America region accounted for more than 45% of the total market of global CRISPR And CRISPR-Associated (Cas) Genes. This report presents a comprehensive overview, market shares, and growth opportunities of CRISPR and CRISPR-Associated (Cas) Genes market by product type, application, key players and key regions and countries. Market Segmentation: Segmentation by type Genome Editing Genetic engineering gRNA Database/Gene Librar CRISPR Plasmid Human Stem Cells Genetically Modified Organisms/Crops Cell Line Engineering Segmentation by application Biotechnology Companies Pharmaceutical Companies Academic Institutes Research and Development Institutes This report also splits the market by region: Americas United States Canada Mexico Brazil APAC China Japan Korea Southeast Asia India Australia Europe Germany France UK Italy Russia Middle East & Africa Egypt South Africa Israel Turkey GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration. Thermo Fisher Scientific Editas Medicine Caribou Biosciences CRISPR therapeutics Intellia therapeutics, Inc. Cellectis Horizon Discovery Plc Sigma Aldrich Precision Biosciences Genscript Sangamo Biosciences Inc. Lonza Group Limited Integrated DNA Technologies New England Biolabs Origene Technologies
1 Scope of the Report 1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global CRISPR and CRISPR-Associated (Cas) Genes Market Size 2018-2
